ClinicalTrials.gg
Not yet recruitingNCT06438848Updated Jun 3, 2024

Effects of Lymph Drainage on Patients With Axillary Web Syndrome

An interventional study of Physical therapy program and Physical therapy program with lymphedema drainage in Movement Disorders, sponsored by Taif University. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Taif University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Effects of a physical therapy program combined with manual lymphatic drainage on shoulder pain and function, quality of life, lymphedema incidence in breast cancer patients with axillary web syndrome following axillary dissection: A randomized controlled trial.

Read the detailed description

This study's objective is to assess the effectiveness of physical therapy (PT) combined with manual lymphatic drainage (MLD) on shoulder pain and function, lymphedema, visible cords, and quality of life (QOL), compared to physical therapy alone, in subjects with breast cancer and suffering of axillary web syndrome (AWS).

02

Conditions studied

  • Movement Disorders

Browse trials for

03

In context

Movement Disorders

373 studies on the registry are indexed under Movement Disorders; 104 are open to participants now.

This study's planned enrollment of 34 is below the median of 47 across 222 interventional studies indexed under Movement Disorders.

Browse Movement Disorders studies →

Lead sponsor

Taif University is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • had a breast cancer dissection with lymphadenectomy and/or sentinel lymph node and a subsequent appearance of AWS (diagnosed by physical examination and also by using the Screening Test AWS (ST-AWS)) [35].

    • suffering of pain that exceeds 6-8 points (measured by the numeric rating scale (NRS)) in the region of the cording on the upper/lower arm, elbow, and dorsum site, and
    • have visible or palpable cords in the arm or breast.

Exclusion criteria

Exclusion Criteria:

  • suffering of both acute thrombosis and lymphedema,

    • suffering of skin issues like infections or musculoskeletal conditions like adhesive capsulitis, rheumatoid arthritis, pectoral muscle tightness, and diseases of the rotator cuff, and/or
    • having cording that doesn't involve an arm and only affects the chest or side of the thorax.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Physical therapy program

    group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions

    Other: Physical therapy program

  • Experimental
    Physical therapy program with lymphedema drainage

    physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks

    Other: Physical therapy program with lymphedema drainage

Interventions

  • OtherPhysical therapy program

    group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions

  • OtherPhysical therapy program with lymphedema drainage

    physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity will be assessed using the NRS (0-10). A score of 0 means there is no pain, while a score of 10 means presence of severe pain.

    Time frame: 5 weeks

  2. Disability

    Assessment of disability will be done using the Arabic Quick-DASH questionnaire which is an 11-item self-report questionnaire, The DASH has five response options for each item from 0=no difficulty to perform or no symptoms to 5=unable to do. A higher score reflects greater disability.

    Time frame: 5 weeks

Secondary outcomes

  1. Limb Girth

    The limb girth will be measured using the tape measurement. Upper limb volumes will be calculated from circumference measurements taken at 4-cm intervals from the dorsum of the wrist to the axilla. The diagnostic criterion for lymphedema was ≥3 % volume increase from baseline in the affected upper limb.

    Time frame: 4 weeks

  2. Cording

    lymphedema therapist (PT/CLT) will examine the arm and axilla for any visible or palpable cords. The findings will be either positive for cording or negative. It is a nominal qualitative variable.

    Time frame: 5 weeks

  3. Muscular strength

    Using a hand-held dynamometer, the maximum voluntary isometric contraction of the muscles will be used to assess their strength.

    Time frame: 5 weeks

  4. Range of motion

    The active ROM (AROM) will be assessed using a goniometer which has been proved to have reliability and concurrent validity for measuring shoulder mobility measurements

    Time frame: 5 weeks

  5. Quality of life for participants

    The EORTC QLQ-C30 is a 30-item questionnaire including measuring Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4)

    Time frame: 5 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Aug 2024, 2 months later.

Of 83 non-industry interventional studies with no phase under Movement Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 80. This study's planned 2 months is below that.

Counting every sponsor, half of 85 studies reached it within 33 months; a quarter within 11 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 3, 2024
StartEst.
Jun 2024
Primary completionEst.
Aug 2024
CompletionEst.
Sep 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06438848
Lead sponsor
Taif University
Responsible party
Ibrahim Mohammad Alkayshan (Physical therapist, Taif University) — Principal investigator
First posted
Jun 3, 2024
Start date
Jun 2024 (estimated)
Primary completion
Aug 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Jun 3, 2024

Study contacts

Ibrahim Alkayshan, Bachelorette
Contact
Ibrahim.alkayshan@gmail.com
0096650127261
Alaa Baboor, Bachelorette
Contact
Alaa.s.baboor@hotmail.com
00966596628155
Hassan Alzahrani, PHD
study chair · Taif University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion